PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT
Clinical trial NCT04789434 · UNKNOWN
Trial details
- NCT number
- NCT04789434
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-09
- Primary completion
- 2023-07-01
- Enrollment
- 94
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.